My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

24.21 -0.07 (-0.29%)

Official Closing Price Updated: 7:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

30 31 Next >

Teva and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease

July 25, 2024

From Teva Pharmaceutical Industries Limited

Via Business Wire

Why Hims & Hers Heath Shares Are Surging Today ↗

July 22, 2024

Hims & Hers Health Inc. (NYSE: HIMS) shares are moving higher on Monday amidst the announcement of Kåre Schultz's appointment to the Board of Directors.

Via Benzinga

$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today ↗

July 19, 2024

Via Benzinga

Teva's Migraine Treatment Found Effective For Children As Young As 6 ↗

July 18, 2024

Teva Pharmaceutical's Phase 3 SPACE study reveals Ajovy's significant efficacy in preventing episodic migraines in children aged 6-17. The trial's primary endpoint was met with safety data aligning...

Via Benzinga

Teva Announces First Phase 3 Evidence of Efficacy and Safety of an Anti-CGRP Monoclonal Antibody in Children in AJOVY® (fremanezumab) SPACE Trial for Prevention of Episodic Migraine

July 18, 2024

From Teva Pharmaceutical Industries Limited

Via Business Wire

Breaking Down Teva Pharmaceutical Indus: 5 Analysts Share Their Views ↗

June 27, 2024

Via Benzinga

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today ↗

June 12, 2024

Via Benzinga

Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There' ↗

July 17, 2024

Jim Cramer doesn't favor Fortinet, but owns Palo Alto Networks for charity. Air Products not doing well due to better run company Linde.

Via Benzinga

3 No-Brainer Stocks to Buy With $200 Right Now ↗

July 17, 2024

A modest amount of money can go a long way on Wall Street when it's put to work in innovation-driven businesses.

Via The Motley Fool

Here's How Much $1000 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today ↗

July 16, 2024

Via Benzinga

Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem

July 10, 2024

Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024

Via MarketBeat

4 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know ↗

May 30, 2024

Via Benzinga

Teva Pharmaceutical Indus's Options Frenzy: What You Need to Know ↗

May 22, 2024

Via Benzinga

Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024

July 02, 2024

From Teva Pharmaceutical Industries Limited

Via Business Wire

FTC Crackdown on Teva Pharmaceuticals Over Inhaler Patent Abuse ↗

July 01, 2024

The FTC is investigating Teva Pharmaceuticals for alleged misuse of inhaler patents to block generic competition and maintain high prices in the U.S. while selling the same products for less overseas.

Via Benzinga

Topics Intellectual Property

Dr. Reddy's Labs Stock Sees Improved Technical Strength ↗

June 28, 2024

On Friday, Dr. Reddy's Labs ADR stock earned an upgrade to its Relative Strength (RS) Rating, from 66 to 76.

Via Investor's Business Daily

New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses

June 28, 2024

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020

June 25, 2024

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva Announces Launch of Authorized Generic of Victoza® (liraglutide injection 1.8mg), in the United States

June 24, 2024

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva Engages In Settlement Talks Over Medicare Kickback Allegations ↗

June 18, 2024

Teva Pharmaceutical is negotiating with the DOJ to settle a lawsuit alleging it paid kickbacks through charities to boost Copaxone sales, risking up to $10 billion in damages.

Via Benzinga

Topics Lawsuit

Concerpt Therapeutics Shares Are Trading Lower: What You Need To Know ↗

June 14, 2024

Corcept Therapeutics Inc. (NASDAQ: CORT) shares are trading lower Friday afternoon following a report suggesting Teva Pharmaceuticals Inc. (NYSE: TEVA) has sued the company, accusing it of a monopoly...

Via Benzinga

Topics Lawsuit

7 A-Rated Biotech Stocks Worth Betting on in June ↗

June 14, 2024

A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation.

Via InvestorPlace

What is a Bull Flag Pattern? Explanation and Examples

June 13, 2024

Learn how to identify and trade the bull flag pattern, which is a key tool for spotting continuations in bullish trends.

Via MarketBeat

Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

June 04, 2024

From Teva Pharmaceutical Industries Limited

Via Business Wire

New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)

June 01, 2024

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024

June 01, 2024

From Teva Pharmaceutical Industries Limited

Via Business Wire

2 Generic Drug Makers With Growing Runways

May 31, 2024

Brand name drug costs continue to climb but patients and insurers find respite by migrating to generic or biosimilar versions as patents run out.

Via MarketBeat

Topics Intellectual Property

Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day)

May 29, 2024

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

May 20, 2024

From Teva Pharmaceutical Industries Limited

Via Business Wire

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

May 20, 2024

From Alvotech

Via GlobeNewswire

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

30 31 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.